Viral immunotherapy confers ‘striking’ survival benefit in advanced lung cancer
An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor therapy, phase 2 trial results showed.The benefit observed with CAN-2409 (Candel Therapeutics) plus valacyclovir is “striking” given the trial included pretreated patients with multiple